MARKET

MRNA

MRNA

Moderna
NASDAQ
63.93
-4.36
-6.38%
Opening 12:33 07/16 EDT
OPEN
67.00
PREV CLOSE
68.28
HIGH
67.42
LOW
63.55
VOLUME
2.72M
TURNOVER
--
52 WEEK HIGH
85.60
52 WEEK LOW
22.28
MARKET CAP
25.36B
P/E (TTM)
-7.8472
1D
5D
1M
3M
1Y
5Y
1D
Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology
PUBT · 4h ago
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech
Dow Jones · 4h ago
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech
Seeking Alpha · 4h ago
Moderna announces first participant dosed in Phase 1 trial of mRNA-4200
TipRanks · 4h ago
Arbutus Biopharma receives $178M settlement agreement from Moderna
TipRanks · 5h ago
MODERNA ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1 CLINICAL TRIAL EVALUATING INVESTIGATIONAL TUMOR-TARGETED CANCER ANTIGEN THERAPY IN SOLID TUMORS
Reuters · 5h ago
Arbutus files patent infringement suits against Pfizer, BioNTech over LNP technology
PUBT · 5h ago
*Arbutus Biopharma Announces Intent to Return Capital to Holders >ABUS
Dow Jones · 5h ago
More
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

Webull offers Moderna Inc stock information, including NASDAQ: MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.